The approval of Hibsago has created a new market for a handful of biopharmas, including Gilead, Arrowhead, and Vir, to fill ...

GSK’s Hibsago brings a new mechanism of action to chronic hepatitis B, targeting the genetic instructions the virus uses to ...

The Food and Drug Administration approved Hibsago (bepirovirsen) on Oct. 20, 2026, calling it the first-of-its-kind treatment ...

Aside from RG6540, Roche also discontinued a host of other early-stage assets, including an antisense oligonucleotide for ...

In its own approval announcement on Oct. 20, the FDA hailed Hibsago as a “first-of-its-kind” treatment in chronic hepatitis B ...

The FDA approved Hibsago (bepirovirsen; GSK), the first antisense oligonucleotide for chronic hepatitis B, for use with a nucleos (t)ide analogue in adults without cirrhosis, the agency announced ...

FDA-approved Hibsago could help some adults with chronic hepatitis B stop antiviral therapy. Learn who qualifies, what trials ...

Hibsago, the first FDA-approved antisense oligonucleotide to treat chronic hepatitis B, reduces the amount of virus and hepatitis B surface antigen in the body.

The FDA approved bepirovirsen as the first antisense oligonucleotide for chronic hepatitis B virus infection, alongside existing antiviral therapy for eligible adults without cirrhosis. Bepirovirsen ...

FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up ...

The FDA approved bepirovirsen, the first antisense oligonucleotide for chronic hepatitis B, offering a new treatment with functional cure potential. Bepirovirsen is specifically approved for patients ...

Dublin, Oct. (GLOBE NEWSWIRE) -- "Spinocerebellar Ataxias - Pipeline Insight, 2026" has been added to ResearchAndMarkets.com's offering. The report provides a comprehensive analysis of the global ...